Is the male contraceptive pill coming soon?

By Natalie Morrison

- Last updated on GMT

Related tags: Combined oral contraceptive pill

Male contraceptive pill, coming soon?
A male version of the contraceptive pill could be just around the corner, according to researchers at Texas A&M University.

The team found that a compound called JQ1 was successful as a sperm production inhibitor when used in mice. The formulation also works by reducing sperm mobility.

And though the compound is so far delivered through injection, the team are confident they could soon formulate a pill with the same efficacy.

The discovery could be the answer to an industry search for the male pill, with recent studies suggesting more than 70 per cent of men would be willing to take it were it available.

Furthermore unlike the female pill, which can have side effects such as interfering with hormones, the study suggests JQ1 does not affect testosterone levels at all.

“More good news is that there appear to be no side effects whatsoever,”​ said Qinglei Li, an assistant professor working on the project. “Once the JQ1 was no longer given to the mice, they were back to their normal reproduction rates, and it did not affect mating behavior or the health of the offspring.”

"This is an exciting step in male contraception,"​ Li added. "A compound with more specificity will be needed before clinical trials can be done for humans. It does not mean a male birth control just yet, but it is a great step forward in that direction."

How it works

The compound targets bromodomain, found in the testis-specific protein known as BRDT (Bromodomain testis-specific protein).

When inhibited BRDT has been found to reduce sperm production and motility. However the targeted delivery mechanism is one of the first to do it without affecting hormone levels.

“Unequivocally, JQ1 is a BET family inhibitor that exerts its contraceptive effect on the male germline during the peak of expression of BRDT,”​ the research, published in Cell Journal, says.

“We are currently creating and testing the effects of JQ1 derivatives possessing selectivity for BRDT to extend the favourable therapeutic window of BRDT inhibition for male contraception.”

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us


View more